Anvisa's five-strong board voted unanimously not to approve the Russian vaccine after technical staff had highlighted "inherent risks" and "serious" defects, citing a lack of information guaranteeing its safety, quality and effectiveness.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/2QZ5XBt
via gqrds
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment